The ADC targets TROP2 on tumor cells, is internalized, and releases a topoisomerase I inhibitor (SHR9265) that causes DNA damage and apoptosis; any effect on DNA topoisomerase I–expressing cells occurs only after payload delivery (including possible bystander diffusion), not because they express DNA topoisomerase I.